{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:46:02Z","timestamp":1781801162429,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Isavuconazole (ISA) is a first-line treatment for invasive aspergillosis, with routine therapeutic drug monitoring (TDM) typically deemed unnecessary. Although the drug label and prior studies suggest renal function does not affect ISA pharmacokinetics, our findings in two high-risk patients challenge this perspective, showing an inverse correlation between ISA trough concentrations and estimated glomerular filtration rate (eGFR). Trough concentrations exceeding the reported toxicity threshold were associated with adverse drug reactions (ADRs). Given the limited sample size, large-scale retrospective and prospective studies are urgently needed to confirm the impact of renal function on ISA and to develop individualized TDM strategies that optimize efficacy and minimize toxicity.<\/jats:p>","DOI":"10.3389\/fmed.2025.1625697","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:20:02Z","timestamp":1755580802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Unexpected renal influence on isavuconazole trough concentrations: two case reports and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuya","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40265-015-0398-6","article-title":"Isavuconazonium: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: Isavuconazole","volume":"66","author":"James","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","article-title":"Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics","volume":"73","author":"Townsend","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41409-018-0161-1","article-title":"Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting","volume":"53","author":"Busca","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Australasian antifungal guidelines steering, consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern Med J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus Caspofungin in the treatment of Candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Vital, and I. FungiScope Mucormycosis, Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid Leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of Isavuconazole","volume":"57","author":"McCarthy","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Australasian antifungal guidelines steering, consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern Med J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.00829-23","article-title":"Isavuconazole use and TDM in real-world pediatric practice","volume":"67","author":"Fernandez Ledesma","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e01085-19","DOI":"10.1128\/AAC.01085-19","article-title":"Pharmacokinetics and dialytic clearance of Isavuconazole during in vitro and in vivo continuous renal replacement therapy","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/jcm11195756","article-title":"Variability of Isavuconazole trough concentrations during longitudinal therapeutic drug monitoring","volume":"11","author":"Bolcato","year":"2022","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/myc.13653","article-title":"Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19","volume":"66","author":"Bertram","year":"2023","journal-title":"Mycoses"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"Hohl","year":"2022","journal-title":"Mycoses"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of Isavuconazole: serum concentration variability and success rates for reaching target in comparison with Voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:20:03Z","timestamp":1755580803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1625697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":26,"alternative-id":["10.3389\/fmed.2025.1625697"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1625697","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1625697"}}